Free tool
Oncology stocks
We cover 35 companies grouped under the Oncology theme. The median market value in the group is $4.65B. Across the group, the median move over the past trading day is −0.67%. 82% of the 34 with a 200-day average trade above it. Price change over the past year runs from −4.8% to +425.1% across the middle 80 percent of the group, with a median of +86.8%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
35 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $153.10 | +16.14% | +44.89% | +86.85% |
| AZN | AstraZeneca PLC | $166.27 | −3.60% | −8.27% | +5.09% |
| A1ZN34.SA | AstraZeneca PLC | 143.10 BRL | −2.15% | −13.50% | +0.13% |
| BMY | Bristol-Myers Squibb Company | $67.57 | +6.24% | +27.70% | +47.01% |
| RVMD | Revolution Medicines, Inc. | $215.44 | +17.18% | +172.64% | +466.35% |
| ONC | BeOne Medicines AG | $375.80 | +13.72% | +20.83% | +25.21% |
| BNTX | BioNTech SE | $112.56 | +21.75% | +16.41% | +9.27% |
| INCY | Incyte Corporation | $128.12 | −1.39% | +26.33% | +51.01% |
| GMAB | Genmab A/S | $33.75 | +16.38% | +6.07% | +36.20% |
| EXEL | Exelixis, Inc. | $56.10 | −0.73% | +28.73% | +45.68% |
| SMMT | Summit Therapeutics Inc. | $14.23 | +13.39% | −18.78% | −42.63% |
| NUVL | Nuvalent Inc | $123.96 | 0.00% | +22.93% | +62.83% |
| CGON | CG Oncology, Inc. | $78.42 | +7.99% | +87.65% | +196.15% |
| ERAS | Erasca, Inc. | $19.15 | +5.45% | +433.43% | +1112.03% |
| E2XE34.SA | Exelixis, Inc. | 137.40 BRL | −2.25% | +23.92% | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $100.82 | −1.77% | +49.87% | +77.38% |
| COGT | Cogent Biosciences, Inc. | $36.72 | −9.71% | +5.70% | +196.85% |
| CELC | Celcuity Inc. | $95.08 | +15.30% | −5.44% | +90.31% |
| ELVN | Enliven Therapeutics, Inc. | $60.87 | +13.22% | +291.67% | +194.32% |
| TNGX | Tango Therapeutics, Inc. | $25.47 | −4.43% | +185.22% | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $19.46 | +6.40% | +137.90% | +445.10% |
| IDYA | IDEAYA Biosciences, Inc. | $41.58 | +14.99% | +22.84% | +66.32% |
| RCUS | Arcus Biosciences, Inc. | $30.76 | +13.72% | +32.07% | +191.29% |
| TLX | Telix Pharmaceuticals Limited | $11.13 | +9.22% | +46.06% | −8.02% |
| IMNM | Immunome, Inc. | $28.75 | +23.82% | +38.09% | +188.94% |
| ZLAB | Zai Lab Limited | $26.03 | +39.80% | +50.20% | −20.06% |
| SLS | SELLAS Life Sciences Group, Inc. | $13.73 | +36.08% | +215.63% | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $26.71 | +10.60% | +47.90% | +179.69% |
| NUVB | Nuvation Bio Inc. | $6.96 | +4.04% | −18.88% | +135.93% |
| NBTX | Nanobiotix S.A. | $44.50 | +17.66% | +101.08% | +394.99% |
| URGN | UroGen Pharma Ltd. | $45.94 | +12.38% | +102.29% | +135.11% |
| HCM | HUTCHMED (China) Limited | $12.35 | +10.27% | −9.52% | −17.45% |
| XNCR | Xencor, Inc. Common Stock | $28.44 | +42.41% | +90.62% | +254.61% |
| ZYME | Zymeworks Inc. | $29.31 | +29.61% | +10.09% | +96.28% |
| NVCR | NovoCure Limited | $17.89 | +9.69% | +36.36% | +50.21% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.